GlassScriptPhysician profile
Alyssa Bujnak
NPI 1265921688
$1,934.57
in general payments reported to CMS, 2019-2025
13 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.77 · 2022: $173 · 2023: $199 · 2024: $609 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.27 | 2019-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $477.99 | 2022-2025 | Keytruda, Lynparza |
| Abbvie INC. | $179.32 | 2025 | |
| Pfizer INC. | $135.76 | 2024 | |
| Glaxosmithkline, LLC. | $112.57 | 2023-2025 | Jemperli |
| Karyopharm Therapeutics INC. | $102.98 | 2024 | Xpovio |
| Corcept Therapeutics | $91.46 | 2025 | Korlym |
| Genmab U.S., INC. | $73.79 | 2024 | |
| Eisai INC. | $36.00 | 2023 | |
| Caris Mpi, INC. | $20.21 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $17.47 | 2023 | Elahere |
| Ethicon US, LLC | $13.61 | 2025 | Echelon Circular |
| Medical Device Business Services, INC. | $13.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Bujnak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.